for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AstraZeneca plc

AZN.L

Latest Trade

7,958.00GBp

Change

229.00(+2.96%)

Volume

2,550,450

Today's Range

7,787.00

 - 

7,963.00

52 Week Range

5,871.00

 - 

10,120.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
7,729.00
Open
7,849.00
Volume
2,550,450
3M AVG Volume
38.99
Today's High
7,963.00
Today's Low
7,787.00
52 Week High
10,120.00
52 Week Low
5,871.00
Shares Out (MIL)
1,312.32
Market Cap (MIL)
100,757.90
Forward P/E
26.21
Dividend (Yield %)
2.79

Next Event

AstraZeneca PLC at Credit Suisse Virtual Bus Tour

Latest Developments

More

AstraZeneca Says Crestor To Be Divested To Grünenthal In Europe

19 vaccine 94.1% effective

AstraZeneca Says Forxiga Approved In Japan For Heart Failure

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AstraZeneca plc

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

Industry

Biotechnology & Drugs

Contact Info

1 Francis Crick Avenue

CB2 0AA

United Kingdom

+44.20.73045000

https://www.astrazeneca.com/Home

Executive Leadership

Leif Johansson

Independent Non-Executive Chairman of the Board

Pascal Soriot

Chief Executive Officer, Executive Director

Marc Dunoyer

Chief Financial Officer, Executive Director

Katarina Ageborg

Executive Vice President - Sustainability, Chief Compliance Officer

Fiona Cicconi

Executive Vice President - Human Resources

Key Stats

2.11 mean rating - 28 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

22.5K

2018

22.1K

2019

24.4K

2020(E)

26.5K
EPS (USD)

2017

4.280

2018

3.460

2019

3.500

2020(E)

4.054
Price To Earnings (TTM)
54.31
Price To Sales (TTM)
5.24
Price To Book (MRQ)
11.11
Price To Cash Flow (TTM)
21.54
Total Debt To Equity (MRQ)
183.18
LT Debt To Equity (MRQ)
153.78
Return on Investment (TTM)
5.59
Return on Equity (TTM)
3.93

Latest News

Latest News

Norway to use three vaccines to stop COVID-19 from early 2021

Norway plans to use the three vaccines developed by Moderna, AstraZeneca, Pfizer and BioNTech in its first push to inoculate its population against COVID-19, the country's health minister said on Friday.

Norway to use three vaccines to stop COVID-19 from early 2021

Norway plans to use the three vaccines developed by Moderna, AstraZeneca, Pfizer and BioNTech in its first push to inoculate its population against COVID-19, Norway's health minister said on Friday.

UK Stocks-Factors to watch on Dec. 4

Dec 4 - Futures for Britain's FTSE 100 index were 0.4% higher on Friday. * BREXIT: The European Union and Britain talked into late on Thursday to try to secure a Brexit trade deal, with an EU official saying an agreement was closer than ever but a UK government source warning...

South Korea reaches deal to buy AstraZeneca's COVID-19 vaccine candidate: media

South Korea has reached a deal with AstraZeneca PLC to purchase its coronavirus vaccine candidate as it seeks to secure supplies amid a resurgence of outbreaks, local media reported on Thursday.

UK Stocks-Factors to watch on Dec 3

Britain's FTSE 100 index is seen opening 14 points lower at 6,449 on Thursday, according to financial bookmakers. * ASTRAZENECA: AstraZeneca Plc will likely get results of its U.S. COVID-19 vaccine trial in late-January and could potentially file for an emergency authorization...

AstraZeneca U.S. COVID-19 vaccine trial results likely in late-January, says health official

AstraZeneca Plc will likely get results of its U.S. COVID-19 vaccine trial in late-January and could potentially file for an emergency authorization, the chief adviser for the U.S. government's Operation Warp Speed program said on Wednesday.

Brazil opens route for emergency approval of COVID-19 vaccines

Brazil's health regulator Anvisa said on Wednesday it was open to approving COVID-19 vaccines for emergency use and outlined the requirements for companies looking to do so.

First doses of AstraZeneca vaccine to arrive in Brazil by February, health minister says

The first batch of AstraZeneca's COVID-19 vaccine candidate will arrive in Brazil between January and February next year, Health Minister Eduardo Pazuello said on Wednesday, with 100 million doses to arrive in the first half of 2021.

Explainer: When and how will COVID-19 vaccines become available?

Britain on Wednesday became the first Western country to approve a COVID-19 vaccine, jumping ahead of the United States and Europe after its regulator cleared a shot developed by Pfizer and BioNTech for emergency use in record time.

EXPLAINER-When and how will COVID-19 vaccines become available?

Britain on Wednesday became the first Western country to approve a COVID-19 vaccine, jumping ahead of the United States and Europe after its regulator cleared a shot developed by Pfizer and BioNTech for emergency use in record time.

AstraZeneca partner sticks with two full dose regimen in COVID trials in India

Serum Institute of India, which has partnered with AstraZeneca to manufacture its COVID-19 vaccine, will continue to test a two full dose regimen of the shot despite it showing a lower success rate than a half and full dose regimen in pivotal trials, a top executive told...

Bangladesh expects to receive first COVID vaccines by February

Bangladesh expects to receive its first batch of coronavirus vaccines by February which people will receive free of charge, the health secretary said on Tuesday.

BRIEF-India Govt Official Says May Not Need To Vaccinate Entire Population

* INDIA GOVERNMENT OFFICIAL SAYS ADVERSE EVENT IN SERUM INSTITUTE OF INDIA'S TRIAL OF ASTRAZENECA'S COVID-19 VACCINE WILL NOT IMPACT TIMELINES

AstraZeneca sells former blockbuster cholesterol drug for $320 million

AstraZeneca said on Tuesday it would sell rights to its erstwhile blockbuster cholesterol drug, Crestor, to German pharmaceutical company Gruenenthal GmbH for an upfront payment of $320 million as the British drugmaker focuses on its cancer treatments portfolio.

BRIEF-AstraZeneca Says Crestor To Be Divested To Grünenthal In Europe

* ASTRAZENECA PLC - CRESTOR TO BE DIVESTED TO GRÜNENTHAL IN EUROPE

AstraZeneca sells cholesterol drug rights to Grünenthal for $320 mln

AstraZeneca said on Tuesday it would sell rights to its cholesterol drug, Crestor, to German pharmaceutical company Grünenthal GmbH for an upfront payment of $320 million.

Factbox: When and which COVID-19 vaccines are likely to be available in Asia

Trial data from Pfizer Inc with partner BioNTech SE, Moderna Inc and AstraZeneca Plc has shown their experimental vaccines are effective in preventing the coronavirus. If regulators approve any in coming weeks, the companies have said distribution could begin almost immediately...

PM Johnson says hopes vaccines will be approved before Christmas

British Prime Minister Boris Johnson said on Monday he hoped the leading COVID-19 vaccine candidates would be approved by regulators before Christmas.

BRIEF-AstraZeneca Says Forxiga Approved In Japan For Heart Failure

* ASTRAZENECA PLC - FORXIGA APPROVED IN JAPAN FOR HEART FAILURE

UK Stocks-Factors to watch on Nov 30

Britain's FTSE 100 index is seen opening 11 points lower at 6,357 on Monday, according to financial bookmakers. * RIO TINTO: Rio Tinto will look to a handful of external candidates in a narrowing field for its new chief executive, as the miner tries to win back investors...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up